Dr Klempner and the Oncology Brothers discuss the treatment paradigm for patients with metastatic upper GI cancers.
Various Mechanisms May Inform Nivolumab Use in Gastroesophageal Cancer
Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
DSMB Confirms MaaT013 Efficacy/Benefit in GI-aGvHD
Evaluation of the 1-year overall survival data in the phase 3 ARES trial assessing MaaT013 in GVHD is expected to occur Q4 2025.
Educating Patients and Clinicians on End-of-Life Care and Discussions
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
Ramucirumab Maintenance Combo Shows Benefit in HER2– Gastric/GEJ Cancer
Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.
Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers
Results from the CheckMate649 trial support the use of nivolumab plus chemotherapy in the treatment of advanced gastric cancers.